Advances in respiratory syncytial virus vaccine development
- PMID: 15043390
Advances in respiratory syncytial virus vaccine development
Abstract
Respiratory syncytial virus (RSV) is the most important causative agent of respiratory tract infections. Young children with chronic lung or congenital heart disease are at increased risk for severe disease. Intensive research into a candidate vaccine has yielded live attenuated vaccines and subunit vaccines, which have been studied in humans. Although immunogenic, occurrence of upper respiratory tract infection symptoms with live attenuated vaccine prohibits evaluation in young infants. Subunit vaccines include purified F protein (PFP-1 and -2) and BBG2Na. PFP vaccines are effective in seropositive children, but also induce upper respiratory symptoms. BBG2Na was being investigated in phase III clinical trials, however, further development has now been discontinued. This review discusses recent advances in RSV vaccine development.
Similar articles
-
The future of respiratory syncytial virus vaccine development.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S65-73. doi: 10.1097/01.inf.0000108194.71892.95. Pediatr Infect Dis J. 2004. PMID: 14730272
-
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.J Infect Dis. 2005 Apr 1;191(7):1093-104. doi: 10.1086/427813. Epub 2005 Mar 1. J Infect Dis. 2005. PMID: 15747245 Clinical Trial.
-
Clinical experience with respiratory syncytial virus vaccines.Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S94-9. doi: 10.1097/01.inf.0000053893.15894.ff. Pediatr Infect Dis J. 2003. PMID: 12671459 Review.
-
Human and bovine respiratory syncytial virus vaccine research and development.Comp Immunol Microbiol Infect Dis. 2008 Mar;31(2-3):191-225. doi: 10.1016/j.cimid.2007.07.008. Epub 2007 Aug 27. Comp Immunol Microbiol Infect Dis. 2008. PMID: 17720245 Review.
-
Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1. Pediatr Infect Dis J. 2009. PMID: 19483659 Clinical Trial.
Cited by
-
Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.Hum Vaccin Immunother. 2014;10(3):615-22. doi: 10.4161/hv.27383. Epub 2013 Dec 10. Hum Vaccin Immunother. 2014. PMID: 24326268 Free PMC article.
-
The future for lung disease in children.Thorax. 2007 Dec;62(12):1021-2. doi: 10.1136/thx.2007.090969. Thorax. 2007. PMID: 18025133 Free PMC article.
-
Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice.Vaccine. 2007 Jan 22;25(6):1085-95. doi: 10.1016/j.vaccine.2006.09.081. Epub 2006 Oct 12. Vaccine. 2007. PMID: 17052820 Free PMC article.
-
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.J Virol. 2010 Jan;84(2):1148-57. doi: 10.1128/JVI.01755-09. Epub 2009 Oct 28. J Virol. 2010. PMID: 19864390 Free PMC article.
-
Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families.Eur J Pediatr. 2008 Apr;167(4):395-9. doi: 10.1007/s00431-007-0509-9. Epub 2007 May 31. Eur J Pediatr. 2008. PMID: 17541638
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical